GSK PLC ORD GBP0.3125

Symbol: GSK

This security went ex-dividend on 20/02/2025. Pay date is 10/04/2025

Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.

Invest in this share within an ISA, JISA, SIPP or Investment Account

Overview

Core Data
Latest Dividend Information

Ex-Dividend Date 20 Feb 2025
Pay Date 10 Apr 2025
Total Dividends - Year to Date61
Dividend Yield (%)4.0694

Historical Data & Ratios

Avg Volume Over 10 Days10.0718
Market Cap (M)63501.1400
Price/Earnings (PE)23.6996
Earnings Per Share63.25
Revenue Per Share7.5751
Return on Equity %19.0614

1 Month Performance Chart

One Month Chart

Broker View
Data shown is based on the past 75 days of broker views.

ActionBrokers

Strong Buy4

Buy3

Neutral15

Sell3

Strong Sell0

Brokers 4 3 15 3 0
Consensus

ConsensusNeutral

Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.

Cost and Charges Information

This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product

Account Type

  • Investment Account
  • Stocks & Shares ISA
  • SIPP

Annual charges

These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate

Cost Category % of Investment lump sum costs
Our annual fee

Our annual fee

Includes our platform fee at 0.30% per annum (excluding Charles Stanley Multi Asset Funds and anycash held). The min fee is £60, the max is £600 per annum, plus SIPP administration fee (if applicable, only charged if < £30,000 held) – see here
0.30%
Dealing charges

Dealing charges

Any one-off commission charges associated with investing. Note that government taxes and levies are not included. This does not include any commission credits you may have available
N/A
Product provider costs

Product provider costs

Product provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs
N/A N/A
Total (£)

Total (£)

Costs per annum displayed in monetary value
Total (%)

Total (%)

Costs per annum displayed as a percentage of investment value

Cumulative effect of charges on your investment's return

This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges

lump sum invested with an assumed growth rate of 1 year years
What you might get back at  with no charges applied

What you might get back at  with no charges applied

These are the illustrative values of a  investment after growth and no costs applied at the end of the defined period
Annual charges

Annual charges

These are the annual costs based on an initial investment amount of assuming a net zero growth rate
Effect of charges on return (%)

Effect of charges on return (%)

These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate
Effect of charges on return (£)

Effect of charges on return (£)

These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate
What you might get back at with charges applied

What you might get back at with charges applied

These are the illustrative values of a investment after growth and costs at the end of the defined period

This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use

Charts

  • Chart Options

    Select Timeframe Add a sector as a comparator Add an index as a comparator Add a share as a comparator

      Add a moving average as a comparator Add a lower indicator as a comparator Chart Style Current Comparators

      Company

      Business Summary

      GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes the lead molecule IDRX-42, highly selective tyrosine kinase inhibitor (TKI) that is designed to improve patients with gastrointestinal stromal tumors (GIST).

      Financial Summary

      BRIEF: For the fiscal year ended 31 December 2024, GSK plc revenues increased 3% to £31.38B. Net income decreased 48% to £2.58B. Revenues reflect US segment increase of 4% to £16.38B, Rest of World segment increase of 3% to £14.28B, UK segment increase of 2% to £708M. Net income was offset by Other segment loss increase from £2.04B to £5.13B, Research and Development segment loss increase of 4% to £5.85B, Unallocated segment loss increase of 30% to £342M.

      Financials


      Income Statement - All values are in GBP (M).

      Year Ending

      31/12/2024

      31/12/2023

      31/12/2022

      31/12/2021

      31/12/2020

      31/12/2019

      Total Revenue 31,376.00 30,328.00 29,324.00 24,696.00 24,354.00 33,754.00
      Gross profit 22,559.00 21,965.00 20,857.00 16,690.00 17,033.00 23,586.00
      Operating Profit/Loss 4,027.00 6,746.00 6,433.00 4,321.00 5,979.00 6,961.00
      Profit Before Tax 3,477.00 6,064.00 5,628.00 3,599.00 5,170.00 6,221.00
      Profit After Tax 2,951.00 5,308.00 4,921.00 3,516.00 5,103.00 5,268.00
      Equity Holders of Parent Company 2,575.00 4,928.00 14,956.00 4,385.00 5,749.00 4,645.00
      Minority Interest -961.00 -932.00 -1,167.00 5,576.00 5,582.00 6,329.00


      Balance Sheet - All values are in GBP (M).

      Year Ending

      31/12/2024

      31/12/2023

      31/12/2022

      31/12/2021

      31/12/2020

      31/12/2019

      Total Non-Current Assets 42,466.00 40,361.00 39,377.00 60,429.00 60,184.00 60,201.00
      Total Current Assets 16,997.00 18,644.00 20,769.00 18,674.00 20,247.00 19,491.00
      Total Assets 59,463.00 59,005.00 60,146.00 79,103.00 80,431.00 79,692.00
      Total Liabilities 46,377.00 46,210.00 50,050.00 57,761.00 59,623.00 61,335.00
      Total Net Assets 13,086.00 12,795.00 10,096.00 21,342.00 20,808.00 18,357.00
      Shareholders Funds 13,671.00 13,347.00 10,598.00 15,055.00 14,587.00 11,405.00
      Minority Interests -961.00 -932.00 -1,167.00 5,576.00 5,582.00 6,329.00
      Total Equity 13,086.00 12,795.00 10,096.00 21,342.00 20,808.00 18,357.00

      Outlook

      Broker View
      Data shown is based on the past 75 days of broker views.

      ActionBrokers

      Strong Buy4

      Buy3

      Neutral15

      Sell3

      Strong Sell0

      Brokers 4 3 15 3 0
      Consensus

      ConsensusNeutral

      Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.

      © 2022 Refinitiv, an LSEG business. All rights reserved.

      Forecasts

      Year 2025 2026
      Revenue £32,778.80mn £34,495.40mn
      Pre-tax-Profit £9,388.41mn £10,258.50mn
      EPS £1.69p £1.87p
      EPS Growth 5.83% 10.94%
      P/E 8.78 7.84
      PEG Ratio 1.51 0.72
      Dividend 64.94p 69.49p
      Yield 0.00% 0.00%

      Upgrades & Downgrades (Latest)

      DateBrokerRecommendationPriceOld TargetNew TargetChange
      7th Jan 2025JP Morgan CazenoveReiteration1357p0p0pUnderweight
      11th Dec 2024JP Morgan CazenoveReiteration1340p0p0pUnderweight
      29th Nov 2024Berenberg BankReiteration1335p1820p1600pBuy
      10th Sep 2024Berenberg BankReiteration1671p0p1820pBuy
      3rd Sep 2024DeutscheReiteration1655p0p1850pBuy
      28th Aug 2024Shore CapitalReiteration1651p0p0pBuy
      16th Aug 2024Shore CapitalReiteration1591p0p0pBuy
      14th Aug 2024Berenberg BankReiteration1598p0p1820pBuy
      31st Jul 2024DeutscheReiteration1512p1950p1850pBuy
      29th Jul 2024JP Morgan CazenoveReiteration1557p0p0pUnderweight

      Time & Sales

      All prices are in GBX and times are in GMT. Last 20 trades shown. Trade type is estimated and should be treated as indicative only.

      Date Time Price Volume Type
      14 Mar 2025 12:59 1,508 275 Buy
      14 Mar 2025 12:59 1,508 426 Sell
      14 Mar 2025 12:59 1,508 1,063 Buy
      14 Mar 2025 12:59 1,508 29 Buy
      14 Mar 2025 12:59 1,508 392 Sell
      14 Mar 2025 12:58 1,508 625 Buy
      14 Mar 2025 12:58 1,508 126 Buy
      14 Mar 2025 12:58 1,508 613 Buy
      14 Mar 2025 12:58 1,508 260 Buy
      14 Mar 2025 12:58 1,507.5 318 Sell
      14 Mar 2025 12:58 1,507.5 424 Sell
      14 Mar 2025 12:58 1,507.5 11 Sell
      14 Mar 2025 12:57 1,507.5 182 Sell
      14 Mar 2025 12:57 1,507.5 204 Sell
      14 Mar 2025 12:57 1,507.5 680 Sell
      14 Mar 2025 12:57 1,507.5 148 Sell
      14 Mar 2025 12:57 1,507.5 682 Sell
      14 Mar 2025 12:57 1,507.5 40 Buy
      14 Mar 2025 12:57 1,507.5 294 Buy
      14 Mar 2025 12:57 1,507.5 355 Buy

      Selected data supplied by Thomson Reuters ©  View restrictions.

      VIEW ALL MARKET NEWS

      Investment involves risk. You may get back less than invested.